Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain

Pfizer has called time on a phase 2 trial of its CXCR5 antibody in an autoimmune blood disorder, with the company tight-lipped on whether this is marks end of the road for the asset.